title: Prostate cancer screening.
abstract: Prostate cancer is a common cancer and a leading cause of cancer death in men. It is potentially detectable at early, possibly curative stages through various combinations of testing, including DRE, PSA, and TRUS of the prostate. Still unproven is the effectiveness of prostate cancer treatment, and because of that lack of proof, the optimal screening strategies are also elusive. It is possible that what is known as prostate cancer today may be, in fact, multiple entities with different natural histories, different treatment needs, and, consequently, different screening strategies. The role of informed consent has been suggested as a means to involve patients in the decision process, especially because the literature presents an environment of intense controversy. It is hoped that the PIVOT trial or similar efforts and further research into the basic mechanisms of the disease will provide clearer answers in the future.
authors.affiliation: Department of Family Medicine, University of South Florida College of Medicine, Tampa, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Hostetler
authors.forename: I G
authors.initials: IG
authors.lastname: Mandel
authors.forename: J
authors.initials: J
authors.lastname: Marshburn
mesh_terms: D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016896:Treatment Outcome